The role of pro-inflammatory cytokines in the neuroinflammation and neurogenesis of schizophrenia

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 48, Issue , 2014, Pages 277-286

  Na, Kyoung Sae ^a   Jung, Han Yong ^a   Kim, Yong Ku ^b  

^a Soonchunhyang University   (South Korea)

^b Korea University College of Medicine   (South Korea)

Author keywords

Cytokine; Neurodegeneration; Neurogenesis; Neuroinflammation; Schizophrenia

Indexed keywords

2 AMINO 4 METHYL 5 PHOSPHONO 3 PENTENOIC ACID ETHYL ESTER; ACETYLSALICYLIC ACID; CLOZAPINE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; DISRUPTED IN SCHIZOPHRENIA 1 PROTEIN; DIZOCILPINE; GAMMA INTERFERON; HALOPERIDOL; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; KETAMINE; LEUKEMIA INHIBITORY FACTOR; MINOCYCLINE; NEU DIFFERENTIATION FACTOR; OLANZAPINE; PALIPERIDONE; PERAZINE; RISPERIDONE; SOLUBLE INTERLEUKIN 2 RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; CATATONIA; CYTOKINE PRODUCTION; DISC 1 GENE; DOPAMINERGIC TRANSMISSION; GUTAMATERGIC NEUROTRANSMISSION; HUMAN; INFLAMMATION; INNATE IMMUNITY; MAJOR DEPRESSION; METABOLIC SYNDROME X; MICROGLIA; MISSENSE MUTATION; NEGATIVE SYNDROME; NERVE DEGENERATION; NERVOUS SYSTEM DEVELOPMENT; NERVOUS SYSTEM INFLAMMATION; NEUROTRANSMISSION; NONHUMAN; PATHOGENESIS; POSITIVE SYNDROME; PROTEIN PROTEIN INTERACTION; REVIEW; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; TH1 CELL; TH2 CELL;

ALPHA-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID; AMPA; BBB; BLOOD-BRAIN BARRIER; C-REACTIVE PROTEIN; CATIE; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; CLINICAL ANTIPSYCHOTIC TRIALS OF INTERVENTION EFFECTIVENESS; CNS; COX-1; COX-2; CRP; CSF; CYCLOOXYGENASE-1; CYCLOOXYGENASE-2; CYTOKINE; DISC-1; DISRUPTED-IN-SCHIZOPHRENIA 1; GLYCOPROTEIN 130; GP130; HPA; HYPOTHALAMUS-PITUITARY-ADRENAL; IDO; IFN-Γ; IL-10; IL-12; IL-2; IL-3; IL-4; IL-6; IL-8; INDOLAMINE 2,3-DIOXYGENASE; INTERFERON GAMMA; INTERLEUKIN-10; INTERLEUKIN-12; INTERLEUKIN-2; INTERLEUKIN-3; INTERLEUKIN-4; INTERLEUKIN-6; INTERLEUKIN-8; KYNA; KYNURENIC ACID; LEUKEMIA INHIBITORY FACTOR; LIF; LONG-TERM POTENTIATION; LTP; MAJOR DEPRESSIVE DISORDER; MAPK; MDD; MESSENGER RNA; MITOGEN-ACTIVATED PROTEIN KINASE; MRNA; N-METHYL-D-ASPARTATE; NEURERGULIN-1; NEURODEGENERATION; NEUROGENESIS; NEUROINFLAMMATION; NMDA; NRG-1; POLYI:C; POLYRIBOINOSINIC-POLYRIBOCYTIDILIC ACID; RIBONUCLEIC ACID; RNA; SCHIZOPHRENIA; SGZ; SIL-2R; SINGLE NUCLEOTIDE POLYMORPHISMS; SNPS; SOLUBLE IL-2 RECEPTOR; SUBGRANULAR ZONE; SUBVENTRICULAR ZONE; SVZ; TGF-Β; TH1; TH17; TH2; TNF-R1; TNF-R2; TNF-Α; TNF-Α RECEPTOR 1; TNF-Α RECEPTOR 2; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TYPE 17T HELPER CELL; TYPE 1T HELPER CELLS; TYPE 2T HELPER CELLS;

ANIMALS; CYTOKINES; ENCEPHALITIS; HUMANS; NEUROGENESIS; SCHIZOPHRENIA;

EID: 84888883580     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2012.10.022     Document Type: Review

References (223)

1. Acosta-Rodriguez E.V., Rivino L., Geginat J., Jarrossay D., Gattorno M., Lanzavecchia A., et al. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat Immunol 2007, 8:639-646.
2. Akarasereenont P., Techatrisak K., Chotewuttakorn S., Thaworn A. The induction of cyclooxygenase-2 (COX-2) in cultured endothelial cells treated with serum from preeclampsia is mediated by interleukin-6. J Med Assoc Thai 1999, 82:876-884.
3. Akhondzadeh S., Tabatabaee M., Amini H., Ahmadi Abhari S.A., Abbasi S.H., Behnam B. Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial. Schizophr Res 2007, 90:179-185.
4. Akhondzadeh S., Jafari S., Raisi F., Nasehi A.A., Ghoreishi A., Salehi B., et al. Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. Depress Anxiety 2009, 26:607-611.
5. Aravena O., Pesce B., Soto L., Orrego N., Sabugo F., Wurmann P., et al. Anti-TNF therapy in patients with rheumatoid arthritis decreases Th1 and Th17 cell populations and expands IFN-gamma-producing NK cell and regulatory T cell subsets. Immunobiology 2011, 216:1256-1263.
6. Arslan N., Erdur B., Aydin A. Hormones and cytokines in childhood obesity. Indian Pediatr 2010, 47:829-839.
7. Austin C.P., Ky B., Ma L., Morris J.A., Shughrue P.J. Expression of Disrupted-In-Schizophrenia-1, a schizophrenia-associated gene, is prominent in the mouse hippocampus throughout brain development. Neuroscience 2004, 124:3-10.
8. Badoer E. Microglia: activation in acute and chronic inflammatory states and in response to cardiovascular dysfunction. Int J Biochem Cell Biol 2010, 42:1580-1585.
9. Balschun D., Wetzel W., Del Rey A., Pitossi F., Schneider H., Zuschratter W., et al. Interleukin-6: a cytokine to forget. FASEB J 2004, 18:1788-1790.
10. Banks W.A. Blood-brain barrier transport of cytokines: a mechanism for neuropathology. Curr Pharm Des 2005, 11:973-984.
11. Banks W.A. The blood-brain barrier in psychoneuroimmunology. Neurol Clin 2006, 24:413-419.
12. Banks W.A., Kastin A.J., Durham D.A. Bidirectional transport of interleukin-1 alpha across the blood-brain barrier. Brain Res Bull 1989, 23:433-437.
13. Barry S., Clarke G., Scully P., Dinan T.G. Kynurenine pathway in psychosis: evidence of increased tryptophan degradation. J Psychopharmacol 2009, 23:287-294.
14. Barzilay J.I., Abraham L., Heckbert S.R., Cushman M., Kuller L.H., Resnick H.E., et al. The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study. Diabetes 2001, 50:2384-2389.
15. Bauer S., Patterson P.H. Leukemia inhibitory factor promotes neural stem cell self-renewal in the adult brain. J Neurosci 2006, 26:12089-12099.
16. Beattie E.C., Stellwagen D., Morishita W., Bresnahan J.C., Ha B.K., Von Zastrow M., et al. Control of synaptic strength by glial TNFalpha. Science 2002, 295:2282-2285.
17. Ben Achour S., Pascual O. Glia: the many ways to modulate synaptic plasticity. Neurochem Int 2010, 57:440-445.
18. Bessa O. Acute psychosis due to indomethacin. Conn Med 1994, 58:395-396.
19. Biscaro B., Lindvall O., Tesco G., Ekdahl C.T., Nitsch R.M. Inhibition of microglial activation protects hippocampal neurogenesis and improves cognitive deficits in a transgenic mouse model for Alzheimer's disease. Neurodegener Dis 2012, 9:187-198.
20. Brown A.S., Patterson P.H. Maternal infection and schizophrenia: implications for prevention. Schizophr Bull 2011, 37:284-290.
21. Brown A.S., Cohen P., Harkavy-Friedman J., Babulas V., Malaspina D., Gorman J.M., et al. A.E. Bennett Research Award. Prenatal rubella, premorbid abnormalities, and adult schizophrenia. Biol Psychiatry 2001, 49:473-486.
22. Buller K.M. Role of circumventricular organs in pro-inflammatory cytokine-induced activation of the hypothalamic-pituitary-adrenal axis. Clin Exp Pharmacol Physiol 2001, 28:581-589.
23. Busse S., Busse M., Schiltz K., Bielau H., Gos T., Brisch R., et al. Different distribution patterns of lymphocytes and microglia in the hippocampus of patients with residual versus paranoid schizophrenia: further evidence for disease course-related immune alterations?. Brain Behav Immun 2012, 26(8):1273-1279. [Nov].
24. Cacci E., Claasen J.H., Kokaia Z. Microglia-derived tumor necrosis factor-alpha exaggerates death of newborn hippocampal progenitor cells in vitro. J Neurosci Res 2005, 80:789-797.
25. Carney M.W. Paranoid psychosis with indomethacin. Br Med J 1977, 2:994-995.
26. Carter C.S., Perlstein W., Ganguli R., Brar J., Mintun M., Cohen J.D. Functional hypofrontality and working memory dysfunction in schizophrenia. Am J Psychiatry 1998, 155:1285-1287.
27. Cazzullo C.L., Sacchetti E., Galluzzo A., Panariello A., Adorni A., Pegoraro M., et al. Cytokine profiles in schizophrenic patients treated with risperidone: a 3-month follow-up study. Prog Neuropsychopharmacol Biol Psychiatry 2002, 26:33-39.
28. Chaudhry I.B., Hallak J., Husain N., Minhas F., Stirling J., Richardson P., et al. Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment. J Psychopharmacol 2012, 26:1185-1193.
29. Chen X., Wang X., Hossain S., O'Neill F.A., Walsh D., van den Oord E., et al. Interleukin 3 and schizophrenia: the impact of sex and family history. Mol Psychiatry 2007, 12:273-282.
30. Chen G., Zhang X., Zhang J.Z. Role of osteopontin in synovial Th17 differentiation in rheumatoid arthritis. Arthritis Rheum 2010, 62(10):2900-2908. [Oct].
31. Chun K.S., Surh Y.J. Signal transduction pathways regulating cyclooxygenase-2 expression: potential molecular targets for chemoprevention. Biochem Pharmacol 2004, 68:1089-1100.
32. Coelho F.M., Reis H.J., Nicolato R., Romano-Silva M.A., Teixeira M.M., Bauer M.E., et al. Increased serum levels of inflammatory markers in chronic institutionalized patients with schizophrenia. Neuroimmunomodulation 2008, 15:140-144.
33. Dandona P., Weinstock R., Thusu K., Abdel-Rahman E., Aljada A., Wadden T. Tumor necrosis factor-alpha in sera of obese patients: fall with weight loss. J Clin Endocrinol Metab 1998, 83:2907-2910.
34. Dawirs R.R., Hildebrandt K., Teuchert-Noodt G. Adult treatment with haloperidol increases dentate granule cell proliferation in the gerbil hippocampus. J Neural Transm 1998, 105:317-327.
35. de la Fontaine L., Schwarz M.J., Riedel M., Dehning S., Douhet A., Spellmann I., et al. Investigating disease susceptibility and the negative correlation of schizophrenia and rheumatoid arthritis focusing on MIF and CD14 gene polymorphisms. Psychiatry Res 2006, 144:39-47.
36. DeCarolis N.A., Eisch A.J. Hippocampal neurogenesis as a target for the treatment of mental illness: a critical evaluation. Neuropharmacology 2010, 58:884-893.
37. D'Elios M., Del Prete G. Th1/Th2 balance in human disease. Transplant Proc 1998, 30:2373-2377.
38. DeMarco V.G., Johnson M.S., Whaley-Connell A.T., Sowers J.R. Cytokine abnormalities in the etiology of the cardiometabolic syndrome. Curr Hypertens Rep 2010, 12:93-98.
39. Deng W., Aimone J.B., Gage F.H. New neurons and new memories: how does adult hippocampal neurogenesis affect learning and memory?. Nat Rev Neurosci 2010, 11:339-350.
40. Dheen S.T., Kaur C., Ling E.A. Microglial activation and its implications in the brain diseases. Curr Med Chem 2007, 14:1189-1197.
41. Drzyzga L., Obuchowicz E., Marcinowska A., Herman Z.S. Cytokines in schizophrenia and the effects of antipsychotic drugs. Brain Behav Immun 2006, 20:532-545.
42. Duan X., Chang J.H., Ge S., Faulkner R.L., Kim J.Y., Kitabatake Y., et al. Disrupted-In-Schizophrenia 1 regulates integration of newly generated neurons in the adult brain. Cell 2007, 130:1146-1158.
43. Duman R.S. Depression: a case of neuronal life and death?. Biol Psychiatry 2004, 56:140-145.
44. Dunn A.J., Wang J., Ando T. Effects of cytokines on cerebral neurotransmission. Comparison with the effects of stress. Adv Exp Med Biol 1999, 461:117-127.
45. Eaton W.W., Hayward C., Ram R. Schizophrenia and rheumatoid arthritis: a review. Schizophr Res 1992, 6:181-192.
46. Edwards T.L., Wang X., Chen Q., Wormly B., Riley B., O'Neill F.A., et al. Interaction between interleukin 3 and dystrobrevin-binding protein 1 in schizophrenia. Schizophr Res 2008, 106:208-217.
47. Ekdahl C.T., Kokaia Z., Lindvall O. Brain inflammation and adult neurogenesis: the dual role of microglia. Neuroscience 2009, 158:1021-1029.
48. Ellman L.M., Deicken R.F., Vinogradov S., Kremen W.S., Poole J.H., Kern D.M., et al. Structural brain alterations in schizophrenia following fetal exposure to the inflammatory cytokine interleukin-8. Schizophr Res 2010, 121:46-54.
49. Emsley J.G., Mitchell B.D., Kempermann G., Macklis J.D. Adult neurogenesis and repair of the adult CNS with neural progenitors, precursors, and stem cells. Prog Neurobiol 2005, 75:321-341.
50. Erhardt S., Engberg G. Increased phasic activity of dopaminergic neurones in the rat ventral tegmental area following pharmacologically elevated levels of endogenous kynurenic acid. Acta Physiol Scand 2002, 175:45-53.
51. Erhardt S., Schwieler L., Nilsson L., Linderholm K., Engberg G. The kynurenic acid hypothesis of schizophrenia. Physiol Behav 2007, 92:203-209.
52. Eskes C., Honegger P., Juillerat-Jeanneret L., Monnet-Tschudi F. Microglial reaction induced by noncytotoxic methylmercury treatment leads to neuroprotection via interactions with astrocytes and IL-6 release. Glia 2002, 37:43-52.
53. Esposito K., Nappo F., Marfella R., Giugliano G., Giugliano F., Ciotola M., et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 2002, 106:2067-2072.
54. Falls D.L. Neuregulins: functions, forms, and signaling strategies. Exp Cell Res 2003, 284:14-30.
55. Fan X., Goff D.C., Henderson D.C. Inflammation and schizophrenia. Expert Rev Neurother 2007, 7:789-796.
56. Ford E.S., Giles W.H., Dietz W.H. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002, 287:356-359.
57. Fournier N.M., Andersen D.R., Botterill J.J., Sterner E.Y., Lussier A.L., Caruncho H.J., et al. The effect of amygdala kindling on hippocampal neurogenesis coincides with decreased reelin and DISC1 expression in the adult dentate gyrus. Hippocampus 2010, 20:659-671.
58. Gaughran F., O'Neill E., Sham P., Daly R.J., Shanahan F. Soluble interleukin 2 receptor levels in families of people with schizophrenia. Schizophr Res 2002, 56:235-239.
59. Glezer I., Simard A.R., Rivest S. Neuroprotective role of the innate immune system by microglia. Neuroscience 2007, 147:867-883.
60. Gorwood P., Pouchot J., Vinceneux P., Puechal X., Flipo R.M., De Bandt M., et al. Rheumatoid arthritis and schizophrenia: a negative association at a dimensional level. Schizophr Res 2004, 66:21-29.
61. Goshen I., Kreisel T., Ounallah-Saad H., Renbaum P., Zalzstein Y., Ben-Hur T., et al. A dual role for interleukin-1 in hippocampal-dependent memory processes. Psychoneuroendocrinology 2007, 32:1106-1115.
62. Gould E., McEwen B.S., Tanapat P., Galea L.A., Fuchs E. Neurogenesis in the dentate gyrus of the adult tree shrew is regulated by psychosocial stress and NMDA receptor activation. J Neurosci 1997, 17:2492-2498.
63. Green M.F. What are the functional consequences of neurocognitive deficits in schizophrenia?. Am J Psychiatry 1996, 153:321-330.
64. Grohmann U., Fallarino F., Puccetti P. Tolerance, DCs and tryptophan: much ado about IDO. Trends Immunol 2003, 24:242-248.
65. Gu D., Reynolds K., Wu X., Chen J., Duan X., Reynolds R.F., et al. Prevalence of the metabolic syndrome and overweight among adults in China. Lancet 2005, 365:1398-1405.
66. Haack M., Hinze-Selch D., Fenzel T., Kraus T., Kuhn M., Schuld A., et al. Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis. J Psychiatr Res 1999, 33:407-418.
67. Halim N.D., Weickert C.S., McClintock B.W., Weinberger D.R., Lipska B.K. Effects of chronic haloperidol and clozapine treatment on neurogenesis in the adult rat hippocampus. Neuropsychopharmacology 2004, 29:1063-1069.
68. Hanninen K., Katila H., Saarela M., Rontu R., Mattila K.M., Fan M., et al. Interleukin-1 beta gene polymorphism and its interactions with neuregulin-1 gene polymorphism are associated with schizophrenia. Eur Arch Psychiatry Clin Neurosci 2008, 258:10-15.
69. Harrison P.J., Weinberger D.R. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry 2005, 10:40-68. [image 5].
70. Hashioka S., McGeer P.L., Monji A., Kanba S. Anti-inflammatory effects of antidepressants: possibilities for preventives against Alzheimer's disease. Cent Nerv Syst Agents Med Chem 2009, 9:12-19.
71. Hayley S., Poulter M.O., Merali Z., Anisman H. The pathogenesis of clinical depression: stressor- and cytokine-induced alterations of neuroplasticity. Neuroscience 2005, 135:659-678.
72. Heckers S. Neuroimaging studies of the hippocampus in schizophrenia. Hippocampus 2001, 11:520-528.
73. Henn F.A., Vollmayr B. Neurogenesis and depression: etiology or epiphenomenon?. Biol Psychiatry 2004, 56:146-150.
74. Hinze-Selch D., Pollmacher T. In vitro cytokine secretion in individuals with schizophrenia: results, confounding factors, and implications for further research. Brain Behav Immun 2001, 15:282-318.
75. Holmberg K.H., Patterson P.H. Leukemia inhibitory factor is a key regulator of astrocytic, microglial and neuronal responses in a low-dose pilocarpine injury model. Brain Res 2006, 1075:26-35.
76. Hou Y., Wu C.F., Yang J.Y., He X., Bi X.L., Yu L., et al. Effects of clozapine, olanzapine and haloperidol on nitric oxide production by lipopolysaccharide-activated N9 cells. Prog Neuropsychopharmacol Biol Psychiatry 2006, 30:1523-1528.
77. Igue R., Potvin S., Bah R., Stip E., Bouchard R.H., Lipp O., et al. Soluble interleukin-2 receptor levels correlated with positive symptoms during quetiapine treatment in schizophrenia-spectrum disorders. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35:1695-1698.
78. Iosif R.E., Ekdahl C.T., Ahlenius H., Pronk C.J., Bonde S., Kokaia Z., et al. Tumor necrosis factor receptor 1 is a negative regulator of progenitor proliferation in adult hippocampal neurogenesis. J Neurosci 2006, 26:9703-9712.
79. Jensen O., Lisman J.E. Hippocampal sequence-encoding driven by a cortical multi-item working memory buffer. Trends Neurosci 2005, 28:67-72.
80. Kalkman H.O. Altered growth factor signaling pathways as the basis of aberrant stem cell maturation in schizophrenia. Pharmacol Ther 2009, 121:115-122.
81. Kang S.H., Kim K.H., Kang G.Y., Lee K.H., Kim K.K., Soh M., et al. Cross-sectional prevalence of metabolic syndrome in Korean patients with schizophrenia. Schizophr Res 2011, 128(1-3):179-181. [May].
82. Kato T., Monji A., Hashioka S., Kanba S. Risperidone significantly inhibits interferon-gamma-induced microglial activation in vitro. Schizophr Res 2007, 92:108-115.
83. Kato T., Mizoguchi Y., Monji A., Horikawa H., Suzuki S.O., Seki Y., et al. Inhibitory effects of aripiprazole on interferon-gamma-induced microglial activation via intracellular Ca2+ regulation in vitro. J Neurochem 2008, 106:815-825.
84. Keilhoff G., Bernstein H.G., Becker A., Grecksch G., Wolf G. Increased neurogenesis in a rat ketamine model of schizophrenia. Biol Psychiatry 2004, 56:317-322.
85. Kelly D.L., Vyas G., Richardson C.M., Koola M., McMahon R.P., Buchanan R.W., et al. Adjunct minocycline to clozapine treated patients with persistent schizophrenia symptoms. Schizophr Res 2011, 133:257-258.
86. Kempermann G. Why new neurons? Possible functions for adult hippocampal neurogenesis. J Neurosci 2002, 22:635-638.
87. Kerr B.J., Patterson P.H. Potent pro-inflammatory actions of leukemia inhibitory factor in the spinal cord of the adult mouse. Exp Neurol 2004, 188:391-407.
88. Kim Y.K. The role of cytokine network in the pathophysiology of schizophrenia. Curr Psychiatr Rev 2005, 1:123-131.
89. Kim Y.K., Maes M. The role of the cytokine network in psychological stress. Acta Neuropsychiatr 2003, 15:148-155.
90. Kim Y.K., Lee M.S., Suh K.Y. Decreased interleukin-2 production in Korean schizophrenic patients. Biol Psychiatry 1998, 43:701-704.
91. Kim Y.K., Kim L., Lee M.S. Relationships between interleukins, neurotransmitters and psychopathology in drug-free male schizophrenics. Schizophr Res 2000, 44:165-175.
92. Kim Y.K., Suh I.B., Kim H., Han C.S., Lim C.S., Choi S.H., et al. The plasma levels of interleukin-12 in schizophrenia, major depression, and bipolar mania: effects of psychotropic drugs. Mol Psychiatry 2002, 7:1107-1114.
93. Kim Y.K., Myint A.M., Lee B.H., Han C.S., Lee H.J., Kim D.J., et al. Th1, Th2 and Th3 cytokine alteration in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2004, 28:1129-1134.
94. Kim S.J., Lee B.H., Kim Y.K. Changes of interleukin-12 and transforming growth factor beta 1 before and after antipsychotic treatments in schizophrenic patients. J Korean Soc Biol Psychiatry 2005, 12:143-150.
95. Kim Y.K., Myint A.M., Verkerk R., Scharpe S., Steinbusch H., Leonard B. Cytokine changes and tryptophan metabolites in medication-naive and medication-free schizophrenic patients. Neuropsychobiology 2009, 59:123-129.
96. Kodama M., Fujioka T., Duman R.S. Chronic olanzapine or fluoxetine administration increases cell proliferation in hippocampus and prefrontal cortex of adult rat. Biol Psychiatry 2004, 56:570-580.
97. Koo J.W., Duman R.S. IL-1beta is an essential mediator of the antineurogenic and anhedonic effects of stress. Proc Natl Acad Sci U S A 2008, 105:751-756.
98. Korn T., Bettelli E., Oukka M., Kuchroo V.K. IL-17 and Th17 Cells. Annu Rev Immunol 2009, 27:485-517.
99. Kowalski J., Blada P., Kucia K., Madej A., Herman Z.S. Neuroleptics normalize increased release of interleukin- 1 beta and tumor necrosis factor-alpha from monocytes in schizophrenia. Schizophr Res 2001, 50:169-175.
100. Kowalski J., Labuzek K., Herman Z.S. Flupentixol and trifluperidol reduce secretion of tumor necrosis factor-alpha and nitric oxide by rat microglial cells. Neurochem Int 2003, 43:173-178.
101. Krady J.K., Lin H.W., Liberto C.M., Basu A., Kremlev S.G., Levison S.W. Ciliary neurotrophic factor and interleukin-6 differentially activate microglia. J Neurosci Res 2008, 86:1538-1547.
102. Kristiansen L.V., Huerta I., Beneyto M., Meador-Woodruff J.H. NMDA receptors and schizophrenia. Curr Opin Pharmacol 2007, 7:48-55.
103. Laan W., Grobbee D.E., Selten J.P., Heijnen C.J., Kahn R.S., Burger H. Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2010, 71:520-527.
104. Labuzek K., Kowalski J., Gabryel B., Herman Z.S. Chlorpromazine and loxapine reduce interleukin-1beta and interleukin-2 release by rat mixed glial and microglial cell cultures. Eur Neuropsychopharmacol 2005, 15:23-30.
105. Law A.J., Shannon Weickert C., Hyde T.M., Kleinman J.E., Harrison P.J. Neuregulin-1 (NRG-1) mRNA and protein in the adult human brain. Neuroscience 2004, 127:125-136.
106. Lawson L.J., Perry V.H., Gordon S. Turnover of resident microglia in the normal adult mouse brain. Neuroscience 1992, 48:405-415.
107. Leuner B., Gould E., Shors T.J. Is there a link between adult neurogenesis and learning?. Hippocampus 2006, 16:216-224.
108. Levkovitz Y., Levi U., Braw Y., Cohen H. Minocycline, a second-generation tetracycline, as a neuroprotective agent in an animal model of schizophrenia. Brain Res 2007, 1154:154-162.
109. Levkovitz Y., Mendlovich S., Riwkes S., Braw Y., Levkovitch-Verbin H., Gal G., et al. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry 2010, 71:138-149.
110. Leykin I., Mayer R., Shinitzky M. Short and long-term immunosuppressive effects of clozapine and haloperidol. Immunopharmacology 1997, 37:75-86.
111. Li A.J., Katafuchi T., Oda S., Hori T., Oomura Y. Interleukin-6 inhibits long-term potentiation in rat hippocampal slices. Brain Res 1997, 748:30-38.
112. Liu Y., Ford B.D., Mann M.A., Fischbach G.D. Neuregulin-1 increases the proliferation of neuronal progenitors from embryonic neural stem cells. Dev Biol 2005, 283:437-445.
113. Maes M., Meltzer H.Y., Bosmans E. Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine. Acta Psychiatr Scand 1994, 89:346-351.
114. Maes M., Bosmans E., Calabrese J., Smith R., Meltzer H.Y. Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J Psychiatr Res 1995, 29:141-152.
115. Maes M., Bosmans E., Kenis G., De Jong R., Smith R.S., Meltzer H.Y. In vivo immunomodulatory effects of clozapine in schizophrenia. Schizophr Res 1997, 26:221-225.
116. Maes M., Bocchio Chiavetto L., Bignotti S., Battisa Tura G.J., Pioli R., Boin F., et al. Increased serum interleukin-8 and interleukin-10 in schizophrenic patients resistant to treatment with neuroleptics and the stimulatory effects of clozapine on serum leukemia inhibitory factor receptor. Schizophr Res 2002, 54:281-291.
117. Marballi K., Quinones M.P., Jimenez F., Escamilla M.A., Raventos H., Soto-Bernardini M.C., et al. In vivo and in vitro genetic evidence of involvement of neuregulin 1 in immune system dysregulation. J Mol Med (Berl) 2010, 88:1133-1141.
118. Marchetti L., Klein M., Schlett K., Pfizenmaier K., Eisel U.L. Tumor necrosis factor (TNF)-mediated neuroprotection against glutamate-induced excitotoxicity is enhanced by N-methyl-D-aspartate receptor activation. Essential role of a TNF receptor 2-mediated phosphatidylinositol 3-kinase-dependent NF-kappa B pathway. J Biol Chem 2004, 279:32869-32881.
119. Mastorakos G., Ilias I. Interleukin-6: a cytokine and/or a major modulator of the response to somatic stress. Ann N Y Acad Sci 2006, 1088:373-381.
120. McDonald C., Murray R.M. Early and late environmental risk factors for schizophrenia. Brain Res Brain Res Rev 2000, 31:130-137.
121. McEvoy J.P., Meyer J.M., Goff D.C., Nasrallah H.A., Davis S.M., Sullivan L., et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005, 80:19-32.
122. McGuirk P., Mills K.H. Pathogen-specific regulatory T cells provoke a shift in the Th1/Th2 paradigm in immunity to infectious diseases. Trends Immunol 2002, 23:450-455.
123. McPherson C.A., Aoyama M., Harry G.J. Interleukin (IL)-1 and IL-6 regulation of neural progenitor cell proliferation with hippocampal injury: differential regulatory pathways in the subgranular zone (SGZ) of the adolescent and mature mouse brain. Brain Behav Immun 2011, 25:850-862.
124. Mednick S.A., Machon R.A., Huttunen M.O., Bonett D. Adult schizophrenia following prenatal exposure to an influenza epidemic. Arch Gen Psychiatry 1988, 45:189-192.
125. Meyer U., Feldon J., Schedlowski M., Yee B.K. Towards an immuno-precipitated neurodevelopmental animal model of schizophrenia. Neurosci Biobehav Rev 2005, 29:913-947.
126. Meyer J.M., McEvoy J.P., Davis V.G., Goff D.C., Nasrallah H.A., Davis S.M., et al. Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. Biol Psychiatry 2009, 66:1013-1022.
127. Millar J.K., Wilson-Annan J.C., Anderson S., Christie S., Taylor M.S., Semple C.A., et al. Disruption of two novel genes by a translocation co-segregating with schizophrenia. Hum Mol Genet 2000, 9:1415-1423.
128. Miller A.H., Maletic V., Raison C.L. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry 2009, 65:732-741.
129. Miller B.J., Buckley P., Seabolt W., Mellor A., Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry 2011, 70:663-671.
130. Ming G.L., Song H. Adult neurogenesis in the mammalian central nervous system. Annu Rev Neurosci 2005, 28:223-250.
131. Miyaoka T., Yasukawa R., Yasuda H., Hayashida M., Inagaki T., Horiguchi J. Possible antipsychotic effects of minocycline in patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:304-307.
132. Miyaoka T., Yasukawa R., Yasuda H., Hayashida M., Inagaki T., Horiguchi J. Minocycline as adjunctive therapy for schizophrenia: an open-label study. Clin Neuropharmacol 2008, 31:287-292.
133. Monje M.L., Toda H., Palmer T.D. Inflammatory blockade restores adult hippocampal neurogenesis. Science 2003, 302:1760-1765.
134. Moots R.J., Al-Saffar Z., Hutchinson D., Golding S.P., Young S.P., Bacon P.A., et al. Old drug, new tricks: haloperidol inhibits secretion of proinflammatory cytokines. Ann Rheum Dis 1999, 58:585-587.
135. Mortensen P.B., Norgaard-Pedersen B., Waltoft B.L., Sorensen T.L., Hougaard D., Yolken R.H. Early infections of Toxoplasma gondii and the later development of schizophrenia. Schizophr Bull 2007, 33:741-744.
136. Mosmann T.R., Cherwinski H., Bond M.W., Giedlin M.A., Coffman R.L. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986, 136:2348-2357.
137. Mouri A., Noda Y., Enomoto T., Nabeshima T. Phencyclidine animal models of schizophrenia: approaches from abnormality of glutamatergic neurotransmission and neurodevelopment. Neurochem Int 2007, 51:173-184.
138. Muller N., Empl M., Riedel M., Schwarz M., Ackenheil M. Neuroleptic treatment increases soluble IL-2 receptors and decreases soluble IL-6 receptors in schizophrenia. Eur Arch Psychiatry Clin Neurosci 1997, 247:308-313.
139. Muller N., Riedel M., Scheppach C., Brandstatter B., Sokullu S., Krampe K., et al. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am J Psychiatry 2002, 159:1029-1034.
140. Muller N., Schwarz M.J., Dehning S., Douhe A., Cerovecki A., Goldstein-Muller B., et al. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry 2006, 11:680-684.
141. Muller N., Krause D., Dehning S., Musil R., Schennach-Wolff R., Obermeier M., et al. Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. Schizophr Res 2010, 121:118-124.
142. Muller N., Myint A.M., Schwarz M.J. Kynurenine pathway in schizophrenia: pathophysiological and therapeutic aspects. Curr Pharm Des 2011, 17:130-136.
143. Myint A.M., Kim Y.K. Cytokine-serotonin interaction through IDO: a neurodegeneration hypothesis of depression. Med Hypotheses 2003, 61:519-525.
144. Na K.S., Kim Y.K. Monocytic, Th1 and th2 cytokine alterations in the pathophysiology of schizophrenia. Neuropsychobiology 2007, 56:55-63.
145. Nacher J., Alonso-Llosa G., Rosell D.R., McEwen B.S. NMDA receptor antagonist treatment increases the production of new neurons in the aged rat hippocampus. Neurobiol Aging 2003, 24:273-284.
146. Nasrallah H.A., Hopkins T., Pixley S.K. Differential effects of antipsychotic and antidepressant drugs on neurogenic regions in rats. Brain Res 2010, 1354:23-29.
147. Nathan C. Points of control in inflammation. Nature 2002, 420:846-852.
148. Niu Q., Cai B., Huang Z.C., Shi Y.Y., Wang L.L. Disturbed Th17/Treg balance in patients with rheumatoid arthritis. Rheumatol Int 2012, 32(9):2731-2736. [Sept].
149. Nunes S.O., Matsuo T., Kaminami M.S., Watanabe M.A., Reiche E.M., Itano E.N. An autoimmune or an inflammatory process in patients with schizophrenia, schizoaffective disorder, and in their biological relatives. Schizophr Res 2006, 84:180-182.
150. Nyffeler M., Meyer U., Yee B.K., Feldon J., Knuesel I. Maternal immune activation during pregnancy increases limbic GABAA receptor immunoreactivity in the adult offspring: implications for schizophrenia. Neuroscience 2006, 143:51-62.
151. Okahisa Y., Ujike H., Kunugi H., Ishihara T., Kodama M., Takaki M., et al. Leukemia inhibitory factor gene is associated with schizophrenia and working memory function. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34:172-176.
152. Olney J.W., Newcomer J.W., Farber N.B. NMDA receptor hypofunction model of schizophrenia. J Psychiatr Res 1999, 33:523-533.
153. Osburg B., Peiser C., Domling D., Schomburg L., Ko Y.T., Voigt K., et al. Effect of endotoxin on expression of TNF receptors and transport of TNF-alpha at the blood-brain barrier of the rat. Am J Physiol Endocrinol Metab 2002, 283:E899-E908.
154. Padmavati R., McCreadie R.G., Tirupati S. Low prevalence of obesity and metabolic syndrome in never-treated chronic schizophrenia. Schizophr Res 2010, 121:199-202.
155. Parnet P., Kelley K.W., Bluthe R.M., Dantzer R. Expression and regulation of interleukin-1 receptors in the brain. Role in cytokines-induced sickness behavior. J Neuroimmunol 2002, 125:5-14.
156. Pechnick R.N., Zonis S., Wawrowsky K., Cosgayon R., Farrokhi C., Lacayo L., et al. Antidepressants stimulate hippocampal neurogenesis by inhibiting p21 expression in the subgranular zone of the hipppocampus. PLoS One 2011, 6:e27290.
157. Perry V.H., Andersson P.B., Gordon S. Macrophages and inflammation in the central nervous system. Trends Neurosci 1993, 16:268-273.
158. Perry V.H., Cunningham C., Holmes C. Systemic infections and inflammation affect chronic neurodegeneration. Nat Rev Immunol 2007, 7:161-167.
159. Piontkewitz Y., Bernstein H.G., Dobrowolny H., Bogerts B., Weiner I., Keilhoff G. Effects of risperidone treatment in adolescence on hippocampal neurogenesis, parvalbumin expression, and vascularization following prenatal immune activation in rats. Brain Behav Immun 2012, 26(2):353-363. [Feb].
160. Pollmacher T., Hinze-Selch D., Mullington J. Effects of clozapine on plasma cytokine and soluble cytokine receptor levels. J Clin Psychopharmacol 1996, 16:403-409.
161. Potvin S., Stip E., Sepehry A.A., Gendron A., Bah R., Kouassi E. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry 2008, 63:801-808.
162. Pradhan A.D., Manson J.E., Rifai N., Buring J.E., Ridker P.M. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001, 286:327-334.
163. Prasad S., Semwal P., Deshpande S., Bhatia T., Nimgaonkar V.L., Thelma B.K. Molecular genetics of schizophrenia: past, present and future. J Biosci 2002, 27:35-52.
164. Quagliarello V.J., Wispelwey B., Long W.J., Scheld W.M. Recombinant human interleukin-1 induces meningitis and blood-brain barrier injury in the rat. Characterization and comparison with tumor necrosis factor. J Clin Invest 1991, 87:1360-1366.
165. Raison C.L., Capuron L., Miller A.H. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol 2006, 27:24-31.
166. Rapaport M.H., Bresee C. Serial mitogen-stimulated cytokine production from continuously ill patients with schizophrenia. Neuropsychopharmacology 2010, 35:428-434.
167. Rapaport M.H., Delrahim K.K., Bresee C.J., Maddux R.E., Ahmadpour O., Dolnak D. Celecoxib augmentation of continuously ill patients with schizophrenia. Biol Psychiatry 2005, 57:1594-1596.
168. Rappard F., Muller N. Celecoxib add-on therapy does not have beneficial antipsychotic effects over risperidone alone in schizophrenia. Neuropsychopharmacology 2004, 29:S222.
169. Reif A., Fritzen S., Finger M., Strobel A., Lauer M., Schmitt A., et al. Neural stem cell proliferation is decreased in schizophrenia, but not in depression. Mol Psychiatry 2006, 11:514-522.
170. Reif A., Schmitt A., Fritzen S., Lesch K.P. Neurogenesis and schizophrenia: dividing neurons in a divided mind?. Eur Arch Psychiatry Clin Neurosci 2007, 257:290-299.
171. Ritchie S.A., Connell J.M. The link between abdominal obesity, metabolic syndrome and cardiovascular disease. Nutr Metab Cardiovasc Dis 2007, 17:319-326.
172. Romagnani S., Maggi E., Liotta F., Cosmi L., Annunziato F. Properties and origin of human Th17 cells. Mol Immunol 2009, 47:3-7.
173. Ross C.A., Margolis R.L., Reading S.A., Pletnikov M., Coyle J.T. Neurobiology of schizophrenia. Neuron 2006, 52:139-153.
174. Rossol M., Kraus S., Pierer M., Baerwald C., Wagner U. The CD14(bright) CD16+ monocyte subset is expanded in rheumatoid arthritis and promotes Th17 expansion. Arthritis Rheum 2012, 64(3):671-677. [Mar].
175. Rott R., Herzog S., Fleischer B., Winokur A., Amsterdam J., Dyson W., et al. Detection of serum antibodies to Borna disease virus in patients with psychiatric disorders. Science 1985, 228:755-756.
176. Rudolf S., Peters M., Rothermundt M., Arolt V., Kirchner H. The influence of typical and atypical neuroleptic drugs in the production of interleukin-2 and interferon-gamma in vitro. Neuropsychobiology 2002, 46:180-185.
177. Rummel C., Sachot C., Poole S., Luheshi G.N. Circulating interleukin-6 induces fever through a STAT3-linked activation of COX-2 in the brain. Am J Physiol Regul Integr Comp Physiol 2006, 291:R1316-R1326.
178. Saddichha S., Manjunatha N., Ameen S., Akhtar S. Metabolic syndrome in first episode schizophrenia - a randomized double-blind controlled, short-term prospective study. Schizophr Res 2008, 101:266-272.
179. Saetre P., Emilsson L., Axelsson E., Kreuger J., Lindholm E., Jazin E. Inflammation-related genes up-regulated in schizophrenia brains. BMC Psychiatry 2007, 7:46.
180. Sarkar S., Fox D.A. Targeting IL-17 and Th17 cells in rheumatoid arthritis. Rheum Dis Clin North Am 2010, 36:345-366.
181. Sawamura N., Sawamura-Yamamoto T., Ozeki Y., Ross C.A., Sawa A. A form of DISC1 enriched in nucleus: altered subcellular distribution in orbitofrontal cortex in psychosis and substance/alcohol abuse. Proc Natl Acad Sci U S A 2005, 102:1187-1192.
182. Schmitt A., Weber S., Jatzko A., Braus D.F., Henn F.A. Hippocampal volume and cell proliferation after acute and chronic clozapine or haloperidol treatment. J Neural Transm 2004, 111:91-100.
183. Schumacher J., Laje G., Abou Jamra R., Becker T., Muhleisen T.W., Vasilescu C., et al. The DISC locus and schizophrenia: evidence from an association study in a central European sample and from a meta-analysis across different European populations. Hum Mol Genet 2009, 18:2719-2727.
184. Schurov I.L., Handford E.J., Brandon N.J., Whiting P.J. Expression of disrupted in schizophrenia 1 (DISC1) protein in the adult and developing mouse brain indicates its role in neurodevelopment. Mol Psychiatry 2004, 9:1100-1110.
185. Schwarz M.J., Muller N., Riedel M., Ackenheil M. The Th2-hypothesis of schizophrenia: a strategy to identify a subgroup of schizophrenia caused by immune mechanisms. Med Hypotheses 2001, 56:483-486.
186. Schwieler L., Erhardt S., Erhardt C., Engberg G. Prostaglandin-mediated control of rat brain kynurenic acid synthesis-opposite actions by COX-1 and COX-2 isoforms. J Neural Transm 2005, 112:863-872.
187. Seder R.A., Paul W.E. Acquisition of lymphokine-producing phenotype by CD4+ T cells. Annu Rev Immunol 1994, 12:635-673.
188. Sengupta S., Parrilla-Escobar M.A., Klink R., Fathalli F., Ying Kin N., Stip E., et al. Are metabolic indices different between drug-naive first-episode psychosis patients and healthy controls?. Schizophr Res 2008, 102:329-336.
189. Sigurdsson T., Stark K.L., Karayiorgou M., Gogos J.A., Gordon J.A. Impaired hippocampal-prefrontal synchrony in a genetic mouse model of schizophrenia. Nature 2010, 464:763-767.
190. Smith R.S., Maes M. The macrophage-T-lymphocyte theory of schizophrenia: additional evidence. Med Hypotheses 1995, 45:135-141.
191. Smith S.E., Li J., Garbett K., Mirnics K., Patterson P.H. Maternal immune activation alters fetal brain development through interleukin-6. J Neurosci 2007, 27:10695-10702.
192. Soderlund J., Schroder J., Nordin C., Samuelsson M., Walther-Jallow L., Karlsson H., et al. Activation of brain interleukin-1beta in schizophrenia. Mol Psychiatry 2009, 14:1069-1071.
193. Sommer I.E., de Witte L., Begemann M., Kahn R.S. Nonsteroidal anti-inflammatory drugs in schizophrenia: ready for practice or a good start? A meta-analysis. J Clin Psychiatry 2012, 73:414-419.
194. Song C., Lin A., Kenis G., Bosmans E., Maes M. Immunosuppressive effects of clozapine and haloperidol: enhanced production of the interleukin-1 receptor antagonist. Schizophr Res 2000, 42:157-164.
195. Song X.Q., Lv L.X., Li W.Q., Hao Y.H., Zhao J.P. The interaction of nuclear factor-kappa B and cytokines is associated with schizophrenia. Biol Psychiatry 2009, 65:481-488.
196. Spelman L.M., Walsh P.I., Sharifi N., Collins P., Thakore J.H. Impaired glucose tolerance in first-episode drug-naive patients with schizophrenia. Diabet Med 2007, 24:481-485.
197. Stober G., Ben-Shachar D., Cardon M., Falkai P., Fonteh A.N., Gawlik M., et al. Schizophrenia: from the brain to peripheral markers. A consensus paper of the WFSBP task force on biological markers. World J Biol Psychiatry 2009, 10:127-155.
198. Sugawara N., Yasui-Furukori N., Sato Y., Umeda T., Kishida I., Yamashita H., et al. Prevalence of metabolic syndrome among patients with schizophrenia in Japan. Schizophr Res 2010, 123:244-250.
199. Suzuki M., Nelson A.D., Eickstaedt J.B., Wallace K., Wright L.S., Svendsen C.N. Glutamate enhances proliferation and neurogenesis in human neural progenitor cell cultures derived from the fetal cortex. Eur J Neurosci 2006, 24:645-653.
200. Tancredi V., D'Antuono M., Cafe C., Giovedi S., Bue M.C., D'Arcangelo G., et al. The inhibitory effects of interleukin-6 on synaptic plasticity in the rat hippocampus are associated with an inhibition of mitogen-activated protein kinase ERK. J Neurochem 2000, 75:634-643.
201. Taupin P. Neurogenesis and the effect of antidepressants. Drug Target Insights 2006, 1:13-17.
202. Thakore J.H. Metabolic disturbance in first-episode schizophrenia. Br J Psychiatry Suppl 2004, 47:S76-S79.
203. Tharumaratnam D., Bashford S., Khan S.A. Indomethacin induced psychosis. Postgrad Med J 2000, 76:736-737.
204. Thompson P.M., Vidal C., Giedd J.N., Gochman P., Blumenthal J., Nicolson R., et al. Mapping adolescent brain change reveals dynamic wave of accelerated gray matter loss in very early-onset schizophrenia. Proc Natl Acad Sci U S A 2001, 98:11650-11655.
205. van Berckel B.N., Bossong M.G., Boellaard R., Kloet R., Schuitemaker A., Caspers E., et al. Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study. Biol Psychiatry 2008, 64:820-822.
206. Venkatasubramanian G., Chittiprol S., Neelakantachar N., Naveen M.N., Thirthall J., Gangadhar B.N., et al. Insulin and insulin-like growth factor-1 abnormalities in antipsychotic-naive schizophrenia. Am J Psychiatry 2007, 164:1557-1560.
207. Vita A., De Peri L., Silenzi C., Dieci M. Brain morphology in first-episode schizophrenia: a meta-analysis of quantitative magnetic resonance imaging studies. Schizophr Res 2006, 82:75-88.
208. Vollmayr B., Mahlstedt M.M., Henn F.A. Neurogenesis and depression: what animal models tell us about the link. Eur Arch Psychiatry Clin Neurosci 2007, 257:300-303.
209. Wakade C.G., Mahadik S.P., Waller J.L., Chiu F.C. Atypical neuroleptics stimulate neurogenesis in adult rat brain. J Neurosci Res 2002, 69:72-79.
210. Wang H.D., Dunnavant F.D., Jarman T., Deutch A.Y. Effects of antipsychotic drugs on neurogenesis in the forebrain of the adult rat. Neuropsychopharmacology 2004, 29:1230-1238.
211. Wang W., Shao S., Jiao Z., Guo M., Xu H., Wang S. The Th17/Treg imbalance and cytokine environment in peripheral blood of patients with rheumatoid arthritis. Rheumatol Int 2012, 32(4):887-893. [Apr].
212. Weinberger D.R. Cell biology of the hippocampal formation in schizophrenia. Biol Psychiatry 1999, 45:395-402.
213. Weisberg S.P., McCann D., Desai M., Rosenbaum M., Leibel R.L., Ferrante A.W. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003, 112:1796-1808.
214. Wonodi I., Schwarcz R. Cortical kynurenine pathway metabolism: a novel target for cognitive enhancement in schizophrenia. Schizophr Bull 2010, 36:211-218.
215. Wonodi I., Stine O.C., Sathyasaikumar K.V., Roberts R.C., Mitchell B.D., Hong L.E., et al. Downregulated kynurenine 3-monooxygenase gene expression and enzyme activity in schizophrenia and genetic association with schizophrenia endophenotypes. Arch Gen Psychiatry 2011, 68:665-674.
216. Woodroofe M.N. Cytokine production in the central nervous system. Neurology 1995, 45:S6-S10.
217. Wu M.D., Hein A.M., Moravan M.J., Shaftel S.S., Olschowka J.A., O'Banion M.K. Adult murine hippocampal neurogenesis is inhibited by sustained IL-1beta and not rescued by voluntary running. Brain Behav Immun 2012, 26(2):292-300. [Feb].
218. Yang L., Lindholm K., Konishi Y., Li R., Shen Y. Target depletion of distinct tumor necrosis factor receptor subtypes reveals hippocampal neuron death and survival through different signal transduction pathways. J Neurosci 2002, 22:3025-3032.
219. Zhang Y., Chun Chen D., Long Tan Y., Zhou D.F. A double-blind, placebo-controlled trial of celecoxib addes to risperidone in first-episode and drug-naive patients with schizophrenia. Eur Arch Psychiatry Clin Neurosci 2006, 256:50.
220. Zhang X.Y., Cao L.Y., Song C., Wu G.Y., Chen da C., Qi L.Y., et al. Lower serum cytokine levels in smokers than nonsmokers with chronic schizophrenia on long-term treatment with antipsychotics. Psychopharmacology 2008, 201:383-389.
221. Zhang X.Y., Zhou D.F., Qi L.Y., Chen S., Cao L.Y., Chen da C., et al. Superoxide dismutase and cytokines in chronic patients with schizophrenia: association with psychopathology and response to antipsychotics. Psychopharmacology 2009, 204:177-184.
222. Zhao C., Teng E.M., Summers R.G., Ming G.L., Gage F.H. Distinct morphological stages of dentate granule neuron maturation in the adult mouse hippocampus. J Neurosci 2006, 26:3-11.
223. Zhao L., Jiao Q., Yang P., Chen X., Zhang J., Zhao B., et al. Metabotropic glutamate receptor 5 promotes proliferation of human neural stem/progenitor cells with activation of mitogen-activated protein kinases signaling pathway in vitro. Neuroscience 2011, 192:185-194.